IL260874A - - Google Patents

Info

Publication number
IL260874A
IL260874A IL26087418A IL26087418A IL260874A IL 260874 A IL260874 A IL 260874A IL 26087418 A IL26087418 A IL 26087418A IL 26087418 A IL26087418 A IL 26087418A IL 260874 A IL260874 A IL 260874A
Authority
IL
Israel
Application number
IL26087418A
Other languages
English (en)
Other versions
IL260874B2 (en
IL260874B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL260874A publication Critical patent/IL260874A/en
Publication of IL260874B1 publication Critical patent/IL260874B1/en
Publication of IL260874B2 publication Critical patent/IL260874B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
IL260874A 2016-02-12 2017-02-10 Methods of treatment and prevention of HIV and AIDS IL260874B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US201662297657P 2016-02-19 2016-02-19
PCT/US2017/017283 WO2017139519A1 (en) 2016-02-12 2017-02-10 Methods for treatment and prophylaxis of hiv and aids

Publications (3)

Publication Number Publication Date
IL260874A true IL260874A (https=) 2018-09-20
IL260874B1 IL260874B1 (en) 2023-06-01
IL260874B2 IL260874B2 (en) 2023-10-01

Family

ID=58057333

Family Applications (1)

Application Number Title Priority Date Filing Date
IL260874A IL260874B2 (en) 2016-02-12 2017-02-10 Methods of treatment and prevention of HIV and AIDS

Country Status (37)

Country Link
US (4) US10537589B2 (https=)
EP (1) EP3413897B1 (https=)
JP (4) JP6810972B2 (https=)
KR (4) KR20220126787A (https=)
CN (2) CN113509480A (https=)
AU (3) AU2017217656B2 (https=)
BR (1) BR112018016349A2 (https=)
CA (1) CA3013473C (https=)
CL (1) CL2018002150A1 (https=)
DK (1) DK3413897T3 (https=)
DO (1) DOP2018000183A (https=)
EA (1) EA201891814A1 (https=)
ES (1) ES2953535T3 (https=)
FI (1) FI3413897T3 (https=)
GE (2) GEP20217231B (https=)
HR (1) HRP20230935T1 (https=)
HU (1) HUE063532T2 (https=)
IL (1) IL260874B2 (https=)
JO (1) JOP20170038B1 (https=)
LT (1) LT3413897T (https=)
MD (1) MD3413897T2 (https=)
MX (3) MX2022002925A (https=)
MY (1) MY197090A (https=)
NI (1) NI201800083A (https=)
NZ (1) NZ745065A (https=)
PH (1) PH12018501712A1 (https=)
PL (1) PL3413897T3 (https=)
PT (1) PT3413897T (https=)
RS (1) RS64448B1 (https=)
SG (1) SG11201806783WA (https=)
SI (1) SI3413897T1 (https=)
SV (1) SV2018005733A (https=)
TN (1) TN2018000267A1 (https=)
TW (2) TWI822652B (https=)
UA (1) UA126375C2 (https=)
WO (1) WO2017139519A1 (https=)
ZA (1) ZA201805073B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
CN109893536B (zh) * 2018-07-02 2021-04-27 河南真实生物科技有限公司 4’-取代核苷的晶型、制备和应用
EP3823632B1 (en) 2018-07-17 2025-10-29 Merck Sharp & Dohme LLC Efda in combination with doravirine for use in treating f227c mutated hiv infections
CA3122576C (en) * 2018-12-20 2025-11-25 Merck Sharp & Dohme Llc CRYSTALLINE FORMS OF THE NRTTI COMPOUND OF 4'-ETHYNYL-2-FLUORO-2'-DESOXYADENOSINE
EP3914604B1 (en) 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
CN113811360A (zh) 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权(第2 号)有限公司 用于hiv治疗的化合物
CA3146679A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT831852E (pt) * 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
CN102174038A (zh) 2003-02-19 2011-09-07 耶鲁大学 用于治疗病毒感染的抗病毒核苷
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
US8513205B2 (en) * 2008-04-11 2013-08-20 Yale University Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
MX391226B (es) 2015-09-23 2025-03-21 Merck Sharp & Dohme Llc Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP6934019B2 (ja) * 2016-05-12 2021-09-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ウイルス薬を送達するための薬物送達システム
WO2017222903A1 (en) * 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
CN114206336A (zh) * 2019-08-13 2022-03-18 默沙东公司 用于递送抗病毒剂的药物递送系统
AU2021268584A1 (en) * 2020-05-05 2022-12-01 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents and contraceptives
US20230310309A1 (en) * 2020-08-25 2023-10-05 Merck Sharp & Dohme Llc Injectable depot compositions for the delivery of antiviral agents

Also Published As

Publication number Publication date
KR20210049201A (ko) 2021-05-04
US20200101098A1 (en) 2020-04-02
JP2021001189A (ja) 2021-01-07
MY197090A (en) 2023-05-24
JP2024001206A (ja) 2024-01-09
IL260874B2 (en) 2023-10-01
UA126375C2 (uk) 2022-09-28
JP6810972B2 (ja) 2021-01-13
AU2017217656A1 (en) 2018-08-23
KR20250136420A (ko) 2025-09-16
TW202417010A (zh) 2024-05-01
CN113509480A (zh) 2021-10-19
RS64448B1 (sr) 2023-09-29
FI3413897T3 (fi) 2023-08-25
EA201891814A1 (ru) 2019-01-31
HK1257347A1 (en) 2019-10-18
PL3413897T3 (pl) 2023-10-02
GEP20207190B (en) 2020-12-10
MX2022002924A (es) 2022-12-15
JP7559175B2 (ja) 2024-10-01
NZ784982A (en) 2025-03-28
AU2020202866B2 (en) 2022-04-07
ZA201805073B (en) 2019-05-29
TW201731514A (zh) 2017-09-16
DOP2018000183A (es) 2018-12-31
WO2017139519A1 (en) 2017-08-17
GEAP202014873A (en) 2020-07-27
HRP20230935T1 (hr) 2023-11-24
AU2022201686A1 (en) 2022-03-31
MX390604B (es) 2025-03-20
PT3413897T (pt) 2023-08-28
CA3013473A1 (en) 2017-08-17
CN108697727A (zh) 2018-10-23
AU2022201686B2 (en) 2024-08-08
US12171776B2 (en) 2024-12-24
JP7021314B2 (ja) 2022-02-16
MD3413897T2 (ro) 2023-11-30
KR102317570B1 (ko) 2021-10-25
TN2018000267A1 (en) 2020-01-16
MX2022002925A (es) 2023-02-10
JOP20170038B1 (ar) 2021-08-17
HUE063532T2 (hu) 2024-01-28
US20180055867A1 (en) 2018-03-01
JP7559175B6 (ja) 2024-10-22
BR112018016349A2 (pt) 2018-12-26
ES2953535T3 (es) 2023-11-14
SG11201806783WA (en) 2018-09-27
SV2018005733A (es) 2018-12-14
GEP20217231B (en) 2021-03-25
NI201800083A (es) 2018-10-05
EP3413897B1 (en) 2023-06-14
NZ745065A (en) 2023-11-24
AU2020202866A1 (en) 2020-05-21
PH12018501712A1 (en) 2019-05-15
JP2022062170A (ja) 2022-04-19
EP3413897A1 (en) 2018-12-19
CA3013473C (en) 2021-10-26
TWI911551B (zh) 2026-01-11
US11337991B2 (en) 2022-05-24
IL260874B1 (en) 2023-06-01
KR20180108815A (ko) 2018-10-04
SI3413897T1 (sl) 2023-11-30
MX2018009763A (es) 2018-11-29
US10537589B2 (en) 2020-01-21
CL2018002150A1 (es) 2018-12-14
US20220331350A1 (en) 2022-10-20
JP2019504857A (ja) 2019-02-21
LT3413897T (lt) 2023-08-25
DK3413897T3 (da) 2023-09-18
AU2017217656B2 (en) 2020-01-30
US20250073254A1 (en) 2025-03-06
KR20220126787A (ko) 2022-09-16
TWI822652B (zh) 2023-11-21

Similar Documents

Publication Publication Date Title
CH714036A1 (https=)
BR122021017409A2 (https=)
BR112019002665A2 (https=)
BR112019009263A2 (https=)
IL260874A (https=)
BR112019009262A2 (https=)
BR112019008087A2 (https=)
BR112019009373A2 (https=)
BR202016021748U2 (https=)
CN303549683S (https=)
CN303537567S (https=)
CN303535548S (https=)
CN303536106S (https=)
CN303536127S (https=)
CN303536212S (https=)
CN303536216S (https=)
CN303536221S (https=)
CN303536278S (https=)
CN303536284S (https=)
CN303536357S (https=)
CN303536361S (https=)
CN303536428S (https=)
CN303536593S (https=)
CN303536597S (https=)
CN303536736S (https=)